BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Royal Bank of Canada

Royal Bank of Canada upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a sector perform rating to an outperform rating in a research note issued to investors on Tuesday, January 2nd, MarketBeat reports. They currently have $6.00 price objective on the biotechnology company’s stock.

A number of other research firms have also recently commented on BCRX. Barclays began coverage on BioCryst Pharmaceuticals in a report on Wednesday, December 20th. They set an equal weight rating and a $6.00 price target for the company. Piper Jaffray Companies reiterated an overweight rating and set a $15.00 price target (up previously from $13.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 5th. HC Wainwright reiterated a buy rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Wednesday, September 6th. JPMorgan Chase & Co. lifted their price target on BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the stock a neutral rating in a report on Wednesday, September 6th. Finally, Jefferies Group upgraded BioCryst Pharmaceuticals from a hold rating to a buy rating and lifted their price target for the stock from $5.00 to $7.00 in a report on Wednesday, September 6th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. BioCryst Pharmaceuticals presently has an average rating of Hold and a consensus price target of $8.63.

BioCryst Pharmaceuticals (NASDAQ BCRX) traded up $0.02 during trading hours on Tuesday, hitting $5.67. The company had a trading volume of 787,000 shares, compared to its average volume of 1,194,318. The company has a current ratio of 2.53, a quick ratio of 2.53 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $560.91, a P/E ratio of -8.86 and a beta of 3.05. BioCryst Pharmaceuticals has a twelve month low of $3.95 and a twelve month high of $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) EPS for the quarter, hitting analysts’ consensus estimates of ($0.18). BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. The business had revenue of $8.76 million during the quarter, compared to analysts’ expectations of $5.05 million. During the same quarter last year, the company posted ($0.16) earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was up 12.9% on a year-over-year basis. research analysts anticipate that BioCryst Pharmaceuticals will post -0.71 EPS for the current year.

In other news, CMO William P. Sheridan sold 64,310 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $4.72, for a total transaction of $303,543.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 5.80% of the company’s stock.

Large investors have recently modified their holdings of the company. Legal & General Group Plc boosted its holdings in shares of BioCryst Pharmaceuticals by 4.9% during the second quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 860 shares during the period. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of BioCryst Pharmaceuticals in the third quarter valued at approximately $132,000. SG Americas Securities LLC raised its position in shares of BioCryst Pharmaceuticals by 98.6% in the third quarter. SG Americas Securities LLC now owns 26,990 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 13,402 shares in the last quarter. Pacad Investment Ltd. acquired a new stake in shares of BioCryst Pharmaceuticals in the second quarter valued at approximately $196,000. Finally, Voya Investment Management LLC raised its position in shares of BioCryst Pharmaceuticals by 12.1% in the second quarter. Voya Investment Management LLC now owns 38,275 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 4,127 shares in the last quarter. Institutional investors own 84.69% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://stocknewstimes.com/2018/01/18/biocryst-pharmaceuticals-bcrx-upgraded-to-outperform-at-royal-bank-of-canada.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply